Core Insights - SINTX Technologies, Inc. has sold its wholly-owned subsidiary, Technology Assessment and Transfer (TA&T), to Tethon Corporation, marking a strategic move to enhance financial flexibility and focus on high-growth opportunities in the medical device sector [1][2][3] Financial Impact - The divestment reduces corporate liabilities by $750,000 and lowers annual operating expenses by more than $1.7 million, improving the company's financial position [2][3] Strategic Focus - The sale aligns with SINTX's strategy to concentrate on commercializing bioceramic technologies aimed at improving patient outcomes and enhancing medical implants and devices [2][3] - The company is committed to advancing its proprietary silicon nitride-based technologies, which have been utilized in human implants since 2008, indicating confidence in its core technologies for long-term value creation [3][4]

Core Insights - SINTX Technologies, Inc. has been granted U.S. Patent No. 12,239,761, enhancing its intellectual property portfolio and solidifying its leadership in silicon nitride innovation [1][2][5] - The patent focuses on advancements in silicon nitride material processing and applications, particularly in the biomedical sector, which is crucial for next-generation implant technology [2][3] - The company is the only FDA-registered producer of implantable silicon nitride, with a diverse portfolio aimed at improving implant longevity and patient safety [4][6] Intellectual Property and Innovation - The newly issued patent covers innovative methods for adhering silicon nitride to various biomaterial substrates, improving biocompatibility and infection resistance [3] - SINTX's intellectual property portfolio now includes 17 issued U.S. patents and 84 pending applications worldwide, reflecting its commitment to innovation [5] Market Position and Applications - SINTX is recognized as a global leader in the research, development, and manufacturing of silicon nitride, with products implanted in humans since 2008 [6] - The company's innovations target orthopedic, craniomaxillofacial, dental, and spinal implants, aligning with its mission to enhance patient outcomes and surgical success rates [3][4]

Core Insights - SINTX Technologies has received a Notice of Allowance from the USPTO for its patent application titled "Methods of Silicon Nitride Laser Cladding," highlighting its leadership in biomaterial innovation and strengthening its intellectual property portfolio [1][5] - The patent protects a novel method for laser bonding bioactive silicon nitride to various biomedical implant substrates, enhancing their biological performance through superior osseointegration and bacterial resistance [2][3] - SINTX is the only FDA-registered producer of implantable silicon nitride, with a focus on expanding its technology applications across diverse markets [4][5] Intellectual Property and Innovation - The company now holds 17 issued U.S. patents and 84 pending patent applications globally, reinforcing its position as a leader in advanced ceramics and biomaterial innovation [5] - The newly allowed patent complements a recently granted U.S. Patent (US 12162807), expanding SINTX's capabilities in enhancing traditional implantable device materials [3] Market Position and Strategy - SINTX's advancements in silicon nitride technology open new opportunities in the biomedical field and provide innovative pathways for upgrading existing medical devices [3][4] - The company has been involved in strategic acquisitions and alliances to enter new markets, with manufacturing and R&D facilities located in Utah and Maryland [6]

Core Insights - SINTX Technologies has signed a Joint Development Agreement (JDA) with NED Medical Inc. to develop advanced ceramic-based microspheres for radiotherapeutic applications [1][2] - The collaboration aims to transition the microsphere process from R&D to pilot production, focusing on preclinical testing and regulatory submissions [2][4] Group 1: Partnership Details - The partnership will leverage SINTX's ceramic manufacturing expertise to support NED Medical's preclinical testing and process validation [2] - SINTX has successfully manufactured ceramic-based microspheres containing Yttrium-90 that meet NED Medical's specifications for a TARE device targeting hepatocellular carcinoma [2][3] - The engineered microspheres feature porosity, allowing for future adaptations in targeted chemotherapy and combination therapies [2] Group 2: Strategic Implications - This partnership signifies SINTX's strategic expansion into the high-growth field of radio therapeutics, a market expected to grow significantly in the coming years [4] - SINTX's proprietary ceramic microsphere technology is anticipated to optimize dosing and enhance treatment precision, positioning the company as a leader in targeted radio-therapeutic devices [4][5] - The agreement opens avenues for future collaborations, including scaling production and expanding indications within oncology and musculoskeletal areas [4] Group 3: Leadership and Innovation - The partnership is expected to transform cancer treatment and underscores SINTX's commitment to advancing innovative solutions in oncological therapies [3] - Dr. Ryan Bock, CTO of SINTX, will join NED Medical's Scientific Advisory Board to guide the clinical development of CombiSphere [3]

Core Insights - SINTX Technologies, Inc. has appointed Gregg R. Honigblum as Chief Strategy Officer to lead corporate strategy and growth initiatives [2][5] - Honigblum has over 35 years of experience in the healthcare sector, including investment banking and executive roles in emerging growth companies [3][4] - His previous successes include raising over $500 million for various ventures and being instrumental in early-stage investments in notable companies like Myriad Genetics and Acacia Biosciences [4] Company Overview - SINTX Technologies specializes in advanced ceramics for medical and technical applications, particularly in the development and commercialization of silicon nitride [6] - The company has been a leader in research, development, and manufacturing since 2008, with facilities in Utah and Maryland [6] - SINTX has utilized strategic acquisitions and alliances to expand into new markets [6]

Core Viewpoint - SINTX Technologies has announced a stock repurchase program to buy back up to $500,000 of its outstanding common stock, representing approximately 20% of total outstanding shares, reflecting the company's confidence in its strategic direction and commitment to enhancing shareholder value [1][2][3] Strategic Rationale - The stock repurchase initiative aligns with SINTX's focus on optimizing its capital structure and aims to increase the ownership stake of remaining shareholders while enhancing earnings per share [2] - The company views share repurchase programs as an effective method to return capital to shareholders, similar to actions taken by other industry leaders [2] Management Commentary - The CEO of SINTX Technologies expressed belief that the current market undervalues the company's potential, emphasizing that the repurchase program demonstrates confidence in the company's strategic initiatives and commitment to shareholder value [3] Program Details - The stock repurchase program will be managed by Maxim Group, LLC, and does not obligate the company to acquire a specific amount of shares, allowing for flexibility based on market conditions and capital needs [4] - Share repurchases may be conducted through various methods, including open market purchases and accelerated share repurchase transactions [4] Company Overview - SINTX Technologies specializes in advanced ceramics for medical and technical applications, being a global leader in silicon nitride research and manufacturing, with products implanted in humans since 2008 [5] - The company has expanded into new markets through strategic acquisitions and alliances, with manufacturing and R&D facilities located in Utah and Maryland [5]

Core Insights - SINTX Technologies is realigning its resources to focus on high-impact, sustainable markets in the medical device industry, leveraging its advanced materials for innovations in spinal fusion devices, orthopedic implants, and surgical tools [2][3] - The company reported an 18% increase in revenue in Q3 2024 compared to the same quarter last year, driven by heightened demand for its high-tech ceramics [5] - SINTX closed Q3 2024 with $4.8 million in cash, an increase from $3.3 million at year-end 2023, supported by strategic offerings that raised $9.4 million year-to-date [4] Strategic Initiatives - The company has ceased operations of its armor division, incurring a one-time impairment charge of $4.5 million, to reallocate resources towards the medical device market [3] - SINTX is actively pursuing partnerships and collaborations with healthcare institutions and industry leaders to enhance its product offerings [2] - The company is exploring new collaborations with strategic advisory partners to evaluate potential mergers, acquisitions, and business division sales to strengthen its position in the medical device sector [6] Financial Performance - SINTX achieved a total revenue increase of 18% in Q3 2024 compared to the same quarter last year, reflecting strong demand for its products [5] - The company improved its liquidity position, closing the quarter with $4.8 million in cash, up from $3.3 million at the end of 2023 [4]

Salt Lake City, Utah, Oct. 01, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company") an advanced materials company specializing in ceramics for biomedical, aerospace, and industrial applications, is pleased to announce two key executive promotions. Effective immediately Ryan Bock, PhD has been promoted to Chief Technology Officer (CTO) of SINTX Technologies, Inc., and Ann Kutsch has been promoted to President of SINTX Technology Assessment and Transfer (SINTX TA&T), a s ...

Executive Leadership Changes - Eric K Olson has been appointed as the new CEO and President of SINTX Technologies succeeding Dr B Sonny Bal who will continue as Chairman of the Board [1][2] - Mr Olson brings over 30 years of experience as a serial founder and entrepreneur in medical device diagnostic biologic and biomaterial companies including his recent role as Founder CEO and Board Member of Foresite Innovations LLC [3] - Mr Olson previously served as CEO President and Board Member of the company when it was known as Amedica Corporation and played a key role in the company's 2014 IPO and NASDAQ listing [3] Strategic Focus - The company remains focused on accelerating the development and commercialization of its technologies and seeking new opportunities to enhance shareholder value [4] Board Advisor Appointment - Gregg Honigblum has been designated as Board Advisor bringing over 35 years of experience as a financial advisor and Managing Director for FNEX Securities [5] - Mr Honigblum was responsible for raising the company's private equity funding prior to its 2014 IPO and served on the Board of Directors from 2006 to 2013 [5] Company Overview - SINTX Technologies is an advanced ceramics company specializing in materials components and technologies for medical and technical applications [6] - The company is a global leader in silicon nitride research development and manufacturing with products implanted in humans since 2008 [6] - SINTX has expanded into new markets through strategic acquisitions and alliances and operates manufacturing and R&D facilities in Utah and Maryland [6]

Salt Lake City, Utah., June 18, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company") today announced that its Board of Directors has initiated a process to explore potential strategic options for the Company. "With technologies targeted at the medical, defense, and renewable energy markets, year-over-year growth in revenues, and other commercial opportunities in the pipeline, SINTX will require additional investment and resources. As such, we want to examine all strate ...